Intellectia LogoIntellectia
Product
Resources
Markets
News
Partner Program
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Quant AI
Stock Chart Patterns
Daytrading Center
AI Earnings Prediction
Whales Auto Tracker
Backtesting Playground

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Tools
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks

News

Trading News
Overview
Top News
Daily Market Brief
Earnings
Latest
Newswire
Stock News
Crypto News
Monitor News
Partner ProgramPricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. ACON
stocks logo

ACON

-
collectAdd to Watchlistadvanced chartAdvanced Chart
$
0.000
0(0.000%)1D
collectadvanced chart
    Overview
    Forecast
    Valuation
    Earnings
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
Intellectia AI SwingMax
Intellectia AI SwingMax

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q3
FY2025Q4
20.00K
+95.5%
-2.640
-99.81%
25.00K
+31.65%
-3.600
-99.78%
Estimates Revision
The market is revising Downward the revenue expectations for Aclarion, Inc. (ACON) for FY2025, with the revenue forecasts being adjusted by -14.44% over the past three months. During the same period, the stock price has changed by -17.10%.
Revenue Estimates for FY2025
Revise Downward
down Image
-14.44%
In Past 3 Month
EPS Estimates for FY2025
Revise Upward
up Image
+0.33%
In Past 3 Month
Stock Price
Go Down
down Image
-17.10%
In Past 3 Month
Wall Street analysts forecast ACON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACON is 23.00 USD with a low forecast of 23.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Analyst Rating
Wall Street analysts forecast ACON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACON is 23.00 USD with a low forecast of 23.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 6.400
sliders
Low
23.00
Averages
23.00
High
23.00
Current: 6.400
sliders
Low
23.00
Averages
23.00
High
23.00
Maxim Group
Anthony Vendetti
Strong Buy
to
Hold
Downgrades
n/a
2024-12-13
Reason
Maxim Group
Anthony Vendetti
Price Target
n/a
2024-12-13
Downgrades
Strong Buy
to
Hold
Reason
Maxim downgraded Aclarion to Hold from Buy.
See All Ratings

Valuation Metrics

The current forward P/E ratio for Aclarion Inc (ACON.O) is -0.48, compared to its 5-year average forward P/E of -1.21. For a more detailed relative valuation and DCF analysis to assess Aclarion Inc 's fair value, click here.
  • Forward PE
  • Forward EV/EBITDA
  • Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-1.21
Current PE
-0.48
Overvalued PE
-0.24
Undervalued PE
-2.18

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
27.60
Current PS
0.00
Overvalued PS
63.76
Undervalued PS
-8.56
AI Stock Picker
AI Stock Picker

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

  • Insider
  • Hedge Fund
  • Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Financial AI Agent
Financial AI Agent

ACON News & Events

Events Timeline

(ET)
2025-12-02
08:10:00
Aclarion Appoints Jason Brosniak as Eastern U.S. Commercial Director
select
2025-10-01 (ET)
2025-10-01
07:22:45
Aclarion Showcases Nociscan Technology at LSI Europe '25
select
2025-09-25 (ET)
2025-09-25
06:06:13
Aclarion Reports Initial Enrollment in Key CLARITY Trial
select
Sign Up For More Events
Sign Up For More Events

News

[object Object]
Preview
4.0
11-20Benzinga
Nvidia Set to Surge by 72%? Check Out 10 Leading Analyst Predictions for Thursday

  • Analyst Upgrades: Piper Sandler raised the price target for Global-E Online Ltd from $42 to $48 while maintaining an Overweight rating, with shares closing at $35.39.

  • Analyst Downgrades: HC Wainwright & Co. cut the price target for Agios Pharmaceuticals Inc from $56 to $48 but kept a Buy rating, with shares closing at $22.34.

  • Mixed Ratings: TD Cowen reduced the price target for Jack In The Box Inc from $21 to $16, maintaining a Hold rating, while Ascendiant Capital increased Aclarion Inc's target from $22 to $23, keeping a Buy rating.

  • Price Target Adjustments: Bernstein adjusted the price targets for several companies, raising Lowe's from $282 to $284 and cutting Target Corp from $87 to $80, while maintaining respective Outperform and Underperform ratings.

[object Object]
Preview
4.0
11-20Benzinga
Ascendiant Capital Reiterates Buy Rating on Aclarion, Increases Price Target to $23

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, helping them stay informed and make timely decisions in the stock market.

  • Exclusive Content: The platform provides exclusive stories and insights generated by Benzinga reporters, enhancing the trading experience for its users.

  • Community Engagement: Over 10,000 serious traders are part of the Benzinga Pro community, indicating a robust network for sharing market intelligence.

  • Market Winning Tools: Benzinga Pro is designed to equip traders with the tools and information necessary to succeed in the markets daily.

[object Object]
Preview
5.0
11-05Newsfilter
Aclarion Names Dan Isherwood as UK Commercial Director to Enhance Adoption and Expand Market Reach

  • Aclarion's New Hire: Aclarion, Inc. has appointed Dan Isherwood as UK Commercial Director, marking a significant step in their commercial strategy to drive the adoption of their Nociscan technology for chronic low back pain.

  • Market Traction in the UK: Nociscan has gained strong traction in the UK, being reimbursed by three of the top four private insurers, which provides access to over 5.2 million covered lives, facilitating easier access for patients.

  • Nociscan Technology: Nociscan is an innovative SaaS platform that uses Magnetic Resonance Spectroscopy to help physicians differentiate between painful and nonpainful discs in the lumbar spine, potentially improving surgical outcomes.

  • Global Impact of Chronic Pain: Chronic low back pain affects an estimated 266 million people worldwide, highlighting the importance of Aclarion's technology in addressing this widespread health challenge.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Aclarion Inc (ACON) stock price today?

The current price of ACON is 6.4 USD — it has increased 4.75 % in the last trading day.

arrow icon

What is Aclarion Inc (ACON)'s business?

Aclarion, Inc. is a healthcare technology company. The Company leverages magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The Company has developed a software application called NOCISCAN. The product uses the existing MRS capabilities of many commercially available scanners to non-invasively analyze the chemical makeup of intervertebral discs in the spine. The software post-processes the MRS exam data and detects the presence of chemical biomarkers that Aclarion, in conjunction with spine researchers at University of California San Francisco (UCSF), have demonstrated to be associated with degenerative pain and structural integrity of the lumbar discs. After processing the MRS exam data, the Company sends the ordering clinician a report that details how to interpret the results of the MRS exam. The platform used to conduct a NOCISCAN involves a diagnostic report called a Nocigram that identifies discs as painful or not.

arrow icon

What is the price predicton of ACON Stock?

Wall Street analysts forecast ACON stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ACON is 23.00 USD with a low forecast of 23.00 USD and a high forecast of 23.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Aclarion Inc (ACON)'s revenue for the last quarter?

Aclarion Inc revenue for the last quarter amounts to 18.94K USD, increased 31.48 % YoY.

arrow icon

What is Aclarion Inc (ACON)'s earnings per share (EPS) for the last quarter?

Aclarion Inc. EPS for the last quarter amounts to -2.93 USD, decreased -99.78 % YoY.

arrow icon

What changes have occurred in the market's expectations for Aclarion Inc (ACON)'s fundamentals?

The market is revising Downward the revenue expectations for Aclarion, Inc. (ACON) for FY2025, with the revenue forecasts being adjusted by -14.44% over the past three months. During the same period, the stock price has changed by -17.10%.
arrow icon

How many employees does Aclarion Inc (ACON). have?

Aclarion Inc (ACON) has 6 emplpoyees as of December 13 2025.

arrow icon

What is Aclarion Inc (ACON) market cap?

Today ACON has the market capitalization of 4.10M USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram
AppStoreGooglePlay

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings TradingDaytrading CenterAI Earnings PredictionQuant AIWhales Auto TrackerBacktesting Playground
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySecuritySitemap
Start for Free